Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo Controlled, Cross-Over Study to Evaluate the Efficacy, Safety and Tolerability of Daily Oral SCI-110 in Treating Adults With Tourette Syndrome

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind, Placebo Controlled, Cross-Over Study to Evaluate the Efficacy, Safety and Tolerability of Daily Oral SCI-110 in Treating Adults With Tourette Syndrome

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dronabinol/palmitoylethanolamide (Primary) ; Dronabinol
  • Indications Gilles de la Tourette's syndrome
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors SciSparc

    • Most Recent Events

    • 23 Aug 2024 According to a SciSparc media release, company announced the submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration for its phase IIb clinical trial for its proprietary SCI-110 for the treatment of Tourette Syndrome.
    • 23 Nov 2023 Planned End Date changed from 1 Oct 2024 to 1 Aug 2025.
    • 23 Nov 2023 Planned primary completion date changed from 1 Jun 2024 to 1 Aug 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top